Inhibition of Th17 Cell Differentiation as a Treatment for Multiple Sclerosis
Final rept. 30 Sep 2011-29 Sep 2013
SRI INTERNATIONAL MENLO PARK CA
Pagination or Media Count:
The goal of this project is to develop miR-326 small molecule inhibitors SMIs for the treatment of Multiple Sclerosis MS. Our global approach consists of creating stable transfectants with a luciferase reporter gene and 3 target sequence for miR-326. The addition of hsa-miR-326 delivered either by lentivirus or cotransfection results in reduced fluorescence, that can be restored by the addition of inhibitors of miR-326. Our efforts to develop a screening method for miR-326 were not successful therefore we were not able to screen compounds. Additionally, experiments aimed to reproduce data showing an association of miR-326 with Th17 cells failed to support that concept. We did not observe any up-regulation of miR326 in Th17 over other T cells.
- Medicine and Medical Research
- Stress Physiology